Phototoxicity occurs when the effects of sunlight and certain drugs converge at the skin level. Various pharmacologic agents have been linked to photosensitivity, including agents used in hematology and oncology. We describe herein a severe phototoxic response to subcutaneous 5-azacitidine. There are no previous reports of phototoxicity reactions to this agent in the published literature. As 5-azacitidine is frequently used to treat patients with myelodysplastic syndromes and acute myeloblastic leukemia, familiarity with this side effect is important for the medical and scientific community at large.
SilvermanLMcKenzieDPetersonB. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol2006; 24: 3895–3903.
2.
KeatingGM. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs2009; 69: 2501–2518.
3.
JunHJKoHRLeeJY. Injection site reaction following 5-azacitidine injection. Ann Dermatol2014; 26: 669–670.
4.
TintleSPatelVRuskinA. Azacitidine: a new medication associated with Sweet syndrome. J Am Acad Dermatol2011; 64: e77–e79.
5.
AlmeidaAMPierdomenicoF. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res2012; 36: e211–e213.
6.
PlatzbeckerUAulCEhningerG. Reduction of 5-azacitidine induced skin reactions in patients with evening primrose oil. Ann Hematol2010; 89: 427–428.
7.
FerruccioLFMurrayCYeeKW. Tolerability of vidaza subcutaneous administration using a maximum volume of 3 ml per injection. J Oncol Pharm Pract2016; 22: 605–610.
8.
MooreDE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf2002; 25: 345–372.
9.
ZhangBBologniaJMarksP. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemother Pharmacol2014; 74: 303–307.
